RxDoctor Payments Data

Adam Zweig, MD

Internal Medicine · San Diego, CANPI 1265527600

Payments from drug & device makers

$420,693in general payments, 2019–2025

Across 1,120 payments — averaging $375.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$320K
  • Gilead$59K
  • EMD Serono, Inc.$29K
  • Janssen Products, LP$6K
  • Theratechnologies Inc.$3K
  • Johnson & Johnson$2K
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$36,4259%
  • Speaking & faculty fees$333,50779%
  • Travel & lodging$26,3056%
  • Food & beverage$24,0146%
  • Education$4420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$420,693 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$40,273
Medicare patients
88
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin64$1,228,680
BiktarvyBictegrav/Emtricit/Tenofov Ala184$717,527
DovatoDolutegravir Sodium/Lamivudine157$444,572
DescovyEmtricitabine/Tenofov Alafenam160$333,235
Egrifta SvTesamorelin Acetate36$292,154
TivicayDolutegravir Sodium90$196,920
PrezcobixDarunavir/Cobicistat53$119,143
OdefseyEmtricitab/Rilpiviri/Tenof Ala29$104,232
CabenuvaCabotegravir/Rilpivirine16$98,609
TriumeqAbacavir/Dolutegravir/Lamivudi18$62,402
IsentressRaltegravir Potassium32$60,302
OzempicSemaglutide34$30,004
JardianceEmpagliflozin49$28,421
EliquisApixaban38$23,188
PifeltroDoravirine13$21,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Serostim$29,159$1,228,68064 claims
GileadBiktarvy, Descovy$58,885$1,050,763344 claims
Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Triumeq$319,874$802,503281 claims
Theratechnologies Inc.Egrifta Sv$3,317$292,15436 claims
Johnson & JohnsonPrezcobix$1,600$119,14353 claims
MerckIsentress, Pifeltro$565$81,74945 claims
PfizerEliquis$121$23,18838 claims
Lilly USA, LLCTrulicity$19$12,33414 claims
Antares Pharma, Inc.Xyosted$17$6,74911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →